{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:09:17Z","timestamp":1788901757217,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018996","name":"Hellenic Academic Libraries Link","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018996","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Probes"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.mcp.2026.102087","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:05:33Z","timestamp":1788390333000},"page":"102087","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Soluble PD-1\/PD-L1 biomarkers in NSCLC: prognostic and diagnostic value"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8907-5786","authenticated-orcid":false,"given":"Konstantinos","family":"Vachlas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8885-2766","authenticated-orcid":false,"given":"Chronis","family":"Fatouros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcp.2026.102087_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051125","article-title":"Precision medicine for NSCLC in the era of immunotherapy: new biomarkers to select the Most suitable treatment or the Most suitable patient","volume":"12","author":"Rossi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.mcp.2026.102087_bib2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/LCTT.S539777","article-title":"Integrated multi-omics approaches for predicting immune checkpoint inhibitor response in NSCLC \u2013 insights from genomics, proteomics, and metabolomics","volume":"16","author":"Elayeh","year":"2025","journal-title":"Lung Cancer Targets Ther."},{"key":"10.1016\/j.mcp.2026.102087_bib3","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1007\/s00262-023-03464-w","article-title":"Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors","volume":"72","author":"Himuro","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.mcp.2026.102087_bib4","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-025-04126-9","article-title":"Soluble PD-L1 (sPD-L1) as a biomarker of durable response and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitors (ICIs)","volume":"74","author":"Costantini","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.mcp.2026.102087_bib5","article-title":"Prognostic significance of programmed cell death ligand 1 blood markers in non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mcp.2026.102087_bib6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cllc.2017.10.014","article-title":"The significance of the PD-L1 expression in Non\u2013small-cell lung cancer: trenchant double swords as predictive and prognostic markers","volume":"19","author":"Takada","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.mcp.2026.102087_bib7","doi-asserted-by":"crossref","DOI":"10.57187\/smw.2023.40110","article-title":"Prognostic implication of PD-L1 in early-stage non-small cell lung cancer: a retrospective single-centre study","author":"Cekani","year":"2023","journal-title":"Swiss Med. Wkly."},{"key":"10.1016\/j.mcp.2026.102087_bib8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s10238-024-01324-0","article-title":"Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients","volume":"24","author":"Mei","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.mcp.2026.102087_bib9","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.21037\/jtd-2019-itm-013","article-title":"Multiomics and machine learning in lung cancer prognosis","volume":"12","author":"Gao","year":"2020","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.mcp.2026.102087_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/JCI179352","article-title":"Soluble immune-checkpoint factors: a potential immunotherapy biomarker","volume":"134","author":"Tan","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.mcp.2026.102087_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/life15040626","article-title":"Soluble PD-L1: from immune evasion to cancer therapy","volume":"15","author":"Dragu","year":"2025","journal-title":"Life"},{"key":"10.1016\/j.mcp.2026.102087_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102948","article-title":"Systematic review: soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC)","volume":"153","author":"Mildner","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.mcp.2026.102087_bib13","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.critrevonc.2019.08.009","article-title":"The clinical significance of soluble PD-1 and PD-L1 in lung cancer","volume":"143","author":"Abu Hejleh","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.mcp.2026.102087_bib14","doi-asserted-by":"crossref","DOI":"10.1172\/JCI168318","article-title":"Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade","volume":"134","author":"Hayashi","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.mcp.2026.102087_bib15","article-title":"The prognostic value of circulating soluble programmed death Ligand-1 in cancers: a meta-analysis","volume":"10","author":"Huang","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mcp.2026.102087_bib16","article-title":"Soluble PD-L1 in NSCLC patients treated with checkpoint inhibitors and its correlation with metabolic parameters","author":"Castello","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.mcp.2026.102087_bib17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2217\/fon-2021-0641","article-title":"Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis","volume":"18","author":"Cheng","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.mcp.2026.102087_bib18","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.cllc.2018.04.014","article-title":"Soluble programmed cell death ligand 1 as a novel biomarker for Nivolumab therapy for Non\u2013small-cell lung cancer","volume":"19","author":"Okuma","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.mcp.2026.102087_bib19","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00262-022-03328-9","article-title":"Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis","volume":"72","author":"Sz\u00e9les","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.mcp.2026.102087_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232214496","article-title":"Soluble PD-L1 as a prognostic factor for immunotherapy treatment in solid tumors: systematic review and meta-analysis","volume":"23","author":"Scirocchi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mcp.2026.102087_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.774131","article-title":"Prognostic role of soluble programmed death ligand 1 in non-small cell lung cancer: a systematic review and meta-analysis","author":"Liao","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mcp.2026.102087_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/jpm16040203","article-title":"Soluble isoforms of PD-1 and PD-L1 in non-small cell lung cancer: correlation with tumor stage, longitudinal analysis and prognostic implications","volume":"16","author":"Vachlas","year":"2026","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.mcp.2026.102087_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1364473","article-title":"Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy","volume":"15","author":"Bar","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mcp.2026.102087_bib24","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1007\/s00262-023-03527-y","article-title":"Prognostic impact of soluble PD-L1 derived from tumor-associated macrophages in non-small-cell lung cancer","volume":"72","author":"Teramoto","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.mcp.2026.102087_bib25","doi-asserted-by":"crossref","DOI":"10.55730\/1300-0144.5407","article-title":"The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in non-small cell lung cancer patients","author":"Ancin","year":"2022","journal-title":"Turk. J. Med. Sci."},{"key":"10.1016\/j.mcp.2026.102087_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1097117","article-title":"Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1\/PD-L1 therapy in non-small cell lung cancer patients","volume":"13","author":"Akbar","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mcp.2026.102087_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.imlet.2018.01.007","article-title":"Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer","volume":"196","author":"Takeuchi","year":"2018","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.mcp.2026.102087_bib28","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-10-0250","article-title":"Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma","author":"Frigola","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mcp.2026.102087_bib29","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1007\/s00262-023-03552-x","article-title":"The influence of plasma sPD-L1 concentration on the effectiveness of immunotherapy in advanced NSCLC patients","volume":"72","author":"Chmielewska","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.mcp.2026.102087_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2016.11.023","article-title":"High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer","author":"Okuma","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.mcp.2026.102087_bib31","doi-asserted-by":"crossref","first-page":"8993","DOI":"10.1038\/s41598-024-59791-0","article-title":"Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy","volume":"14","author":"Brun","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mcp.2026.102087_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cells12060832","article-title":"Prognostic role of soluble and extracellular vesicle-associated PD-L1, B7-H3 and B7-H4 in non-small cell lung cancer patients treated with immune checkpoint inhibitors","volume":"12","author":"Genova","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.mcp.2026.102087_bib33","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-019-2101-2","article-title":"Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients","volume":"17","author":"Li","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.mcp.2026.102087_bib47","article-title":"Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis","volume":"14","author":"Shimizu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mcp.2026.102087_bib39","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.3233\/TUB-230015","article-title":"Missing prognostic value of soluble PD-1, PD-L1 and PD-L2 in lung cancer patients undergoing chemotherapy - a CEPAC-TDM biomarker substudy","volume":"46","author":"Geiger","year":"2024","journal-title":"Tumour Biol"},{"key":"10.1016\/j.mcp.2026.102087_bib40","article-title":"Predictive value of soluble PD-1, PD-L1, VEGFA, CD40 ligand and CD44 for Nivolumab therapy in advanced non-small cell lung cancer: a case-control study","volume":"12","author":"Meyo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.mcp.2026.102087_bib46","first-page":"3585","article-title":"Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody, Thorac","volume":"11","author":"Murakami","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.mcp.2026.102087_bib34","doi-asserted-by":"crossref","DOI":"10.2478\/fco-2023-0036","article-title":"Changes in soluble PD-L1 levels in patients with advanced non-small cell lung cancer","author":"Ta","year":"2024","journal-title":"Forum Clin. Oncol."},{"issue":"1","key":"10.1016\/j.mcp.2026.102087_bib35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12985-022-01777-3","article-title":"The association between sPD-1 levels versus liver biochemistry and viral markers in chronic hepatitis B patients: a comparative study of different sPD-1 assays","volume":"19","author":"Jeng","year":"2022","journal-title":"Virol. J."},{"key":"10.1016\/j.mcp.2026.102087_bib36","article-title":"Research progress of biomarkers in the prediction of anti-PD-1\/PD-L1 immunotherapeutic efficiency in lung cancer","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mcp.2026.102087_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.6879","article-title":"Association of survival and immune-related biomarkers with immunotherapy in patients with non-small cell lung cancer: a meta-analysis and individual patient-level analysis","volume":"2","author":"Yu","year":"2019","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.mcp.2026.102087_bib38","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1186\/s12967-024-05502-2","article-title":"N-linked glycosylation of PD-L1\/PD-1: an emerging target for cancer diagnosis and treatment","volume":"22","author":"Duan","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.mcp.2026.102087_bib41","article-title":"Lack of Association of plasma levels of soluble programmed cell death protein 1, programmed death-ligand 1, and CTLA-4 with survival for stage II to IIIA NSCLC after complete resection and adjuvant chemotherapy","volume":"4","author":"Tanizaki","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.mcp.2026.102087_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9121929","article-title":"Increased plasma soluble PD-1 concentration correlates with disease progression in patients with cancer treated with anti-PD-1 antibodies","author":"Ohkuma","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.mcp.2026.102087_bib43","doi-asserted-by":"crossref","DOI":"10.21037\/atm-22-4218","article-title":"Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments\u2014a systematic review","volume":"11","author":"Olivares-Hern\u00e1ndez","year":"2023","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.mcp.2026.102087_bib44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40364-024-00647-0","article-title":"Soluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications","volume":"12","author":"Chen","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.mcp.2026.102087_bib45","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.3390\/cancers17162639","article-title":"Immune biomarkers for checkpoint blockade in solid tumors: transitioning from tissue to peripheral blood monitoring and future integrated strategies","volume":"17","author":"Trontzas","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.mcp.2026.102087_bib48","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.3390\/diagnostics14192178","article-title":"Enhancing non-small cell lung cancer survival prediction through multi-omics integration using graph attention network","volume":"14","author":"Elbashir","year":"2024","journal-title":"Diagnostics"},{"key":"10.1016\/j.mcp.2026.102087_bib49","first-page":"688","article-title":"Digital immune twins and ai-integrated multi-omic biomarkers: redefining personalized immunotherapy in non-small cell lung cancer, Iran","volume":"29","author":"Abuhassan","year":"2026","journal-title":"J. Basic Med. Sci."},{"key":"10.1016\/j.mcp.2026.102087_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1384731","article-title":"Combination of plasma MMPs and PD-1-binding soluble PD-L1 predicts recurrence in gastric cancer and the efficacy of immune checkpoint inhibitors in non-small cell lung cancer","author":"Ando","year":"2024","journal-title":"Front. Pharmacol."}],"container-title":["Molecular and Cellular Probes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890850826000277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890850826000277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:26:32Z","timestamp":1788899192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890850826000277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":50,"alternative-id":["S0890850826000277"],"URL":"https:\/\/doi.org\/10.1016\/j.mcp.2026.102087","relation":{},"ISSN":["0890-8508"],"issn-type":[{"value":"0890-8508","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Soluble PD-1\/PD-L1 biomarkers in NSCLC: prognostic and diagnostic value","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Probes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcp.2026.102087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102087"}}